Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults

Phathom Pharmaceuticals

Phathom Pharmaceuticals

PHAT

0.00
  • Phathom Pharmaceuticals completed enrollment in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) in adult eosinophilic esophagitis.
  • Topline results for the 12-week double-blind portion are expected in Q4 2026; results have not been presented yet.
  • The placebo-controlled study is designed to assess whether vonoprazan can improve swallowing-related symptoms and disease activity versus placebo.
  • A positive readout could support talks with the FDA on next development steps in EoE, including potential pediatric evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230759PRIMZONEFULLFEED9750816) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.